A new study published in JMIR Dermatology shows that TikTok has become a major source of education and support for people ...

Bimekizumab yields clinically meaningful improvements in the severity of hidradenitis suppurativa over 48 weeks, shifting most patients to a mild disease, a pooled analysis of two trials shows.

Povorcitinib 75 mg achieved high-threshold lesion clearance by week 12, including 100% draining-tunnel reduction in 12%–57% and total abscess clearance in 22%–62% of participants. Phase 3 data show ...

NVS wins CHMP backing for remibrutinib in chronic spontaneous urticaria, bringing its oral BTK inhibitor closer to EU ...

These results suggest that ruxolitinib cream offers high levels of clinical efficacy, including deep and rapid responses, ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsRoopal Thakkar - Executive VP of Research ...

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the ...

Zura Bio Limited ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and ...

After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of its up-and-coming immunology powerhouse. | Two years and five indications later ...

After cutting down its pipeline just a few months ago, OSE Immunotherapeutics is at it again, this time reorganizing as Boehringer Ingelheim walks away from the biotech’s metabolic ...

Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 ...